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Weprovidemicroarray data comparing genome-wide
differential expression and pathology throughout life
in four lines of ‘‘amyloid’’ transgenic mice (mutant hu-
man APP, PSEN1, or APP/PSEN1) and ‘‘TAU’’ trans-
genic mice (mutant human MAPT gene). Microarray
data were validated by qPCR and by comparison to
human studies, including genome-wide association
study (GWAS) hits. Immune gene expression corre-
lated tightly with plaques whereas synaptic genes
correlated negatively with neurofibrillary tangles.
Network analysis of immune gene modules revealed
six hub genes in hippocampus of amyloid mice, four
in common with cortex. The hippocampal network
in TAU mice was similar except that Trem2 had hub
status only in amyloid mice. The cortical network of
TAU mice was entirely different with more hub genes
and few in commonwith the other networks, suggest-
ing reasons for specificity of cortical dysfunction in
FTDP17. This Resource opens up many areas for
investigation. All data are available and searchable
at http://www.mouseac.org.
INTRODUCTION
During the development of Alzheimer’s disease (AD), changes in
gene expression occur at many stages of disease progression.
Early changes may be causal, possibly contributing to initial pa-
thology, whereas later changes may be consequential, due to
synaptic and neuronal damage. Eventually, amyloid and/or tau
deposition and gliosis are thought to result in altered expression
of genes including those of the immune system. Although theseClatter changes have often been thought of as secondary, and
therefore of little note, recent analyses have suggested that ge-
netic variability in immune processes, particularly with respect to
microglial responses, is important in determining the risk of indi-
viduals presenting with the disease. Although mutations in amy-
loid precursor protein (APP) or presenilin 1 (PSEN1) or PSEN2
that lead to raised levels of a range of amyloidb (Ab) peptides
are sufficient to result in Alzheimer’s disease in humans, phos-
phorylation of microtubule-associated protein tau (tau) and the
development of tangles is an essential step in the course of the
disease. The relative contribution of these two elements to
different aspects of the disease is still a matter of controversy.
With this background, we have embarked on a systematic
analysis in which we compare whole-genome expression in
five transgenic mice with human genes for dementia that result
in either plaques or tangle pathology to the expression in wild-
type (WT) control mice and to each other. Microarrays have pre-
viously been used to investigate gene expression in a range of
different studies and have been extensively verified in mice
and humans (Lagraoui et al., 2012; Trabzuni et al., 2011). After
quality control steps, excluding probes or mice with insufficient
signal (see Experimental Procedures), data were available for
12,588 genes and pathology in 113 hippocampus samples,
113 cortex samples, and 111 cerebellum samples. In particular,
we have compared mice transgenic for mutant gene(s) relevant
either to FTDP17: TAU (MAPT: P301L; Hutton et al., 1998) or to
AD: TAS10, amyloid precursor protein (APP: K670N/M671L;
Mullan et al., 1992); TPM, presenilin 1 (PSEN1: M146V); or
TASTPM (APP and PSEN1 [combining the above], heterozygous
[HET] or homozygous [HO]; Howlett and Richardson, 2009). This
analysis allows comparison of the relation of gene expression to
development of neurofibrillary tangles versus development of
amyloid plaques and, in the case of the amyloidmice, also allows
study of dose dependency, as both total Ab and plaque load
develop in these mice at different rates.ell Reports 10, 633–644, February 3, 2015 ª2015 The Authors 633
In all of thesemouse lines, we havemeasured pathology and, in
the samemice, geneexpression changesat 2, 4, 8, and18months
in the hippocampus, cortex, and cerebellum, covering the period
before and during development of plaques or tangles. In this initial
study, we take two approaches. We report an unbiased genome-
wide microarray analysis of mRNA, comparing genotypes across
all ages and brain regions and investigating networks and nodes
that arise when considering all the genes that show differences in
expression compared to WT mice. In addition, we describe
changes in expression of genes known as risk factors from previ-
ous genome-wide association studies (GWASs).
The analysis of data in these different models at ages before
and during the development of pathology in hippocampus,
cortex, and cerebellum greatly extends previous reports of
the increased expression of genes in the immune system as
plaques develop in hippocampus or cortex (Dickey et al., 2003;
Frautschy et al., 1998; Howlett et al., 2008; Reddy et al., 2004;
Stein and Johnson, 2002; Wirz et al., 2013; Wu et al., 2006).
We make all the data publicly available at http://www.
mouseac.org. In addition to access to the full set of data, the
database of normalized genes can be searched across age for
individual gene expression in WT mice and any combination of
the models with both graphical and numerical outputs, thus
providing information relevant to normal aging and to both amy-
loid and TAU models.
RESULTS AND DISCUSSION
Rate and Extent of Development of Amyloid Plaques
and Neurofibrillary Tangles in Mice Used for
Gene-Expression Studies
As we aimed to identify and compare any expression changes
that occur with the development of pathology in the different
models, we investigated the level of amyloid plaque burden
and phosphorylated tau pathology (hippocampus, Figure 1; cor-
tex, Figure S1). For each mouse, mRNA was extracted from one
brain hemisphere and the other hemisphere was used for
immunohistochemistry.
In general, the hippocampus and cortex showed similar pla-
que development. The mouse lines studied showed different
time courses of plaque load progression, allowing us to study
gene-expression changes related to progression of this pathol-
ogy. TASTPM (APP/PSEN1) mice showed the strongest pheno-
type. In agreement with the initial characterization of TASTPM
mice (Howlett and Richardson, 2009), HO-TASTPM started to
show diffuse amyloid staining at 2 months but developed true
plaques by 4 months. In these mice, by 8 months, small plaques
are scattered densely throughout the tissue, and by 18 months,
much of the hippocampus and cortex are covered in large pla-
ques. The HET-TASTPM mice show a similar pattern but devel-
oping more slowly, whereas the TAS10 mice (APP only) also
show plaques but only at 18 months. TPM mice (PSEN1 only)
show no sign of plaques at any time. In contrast, neurofibrillary
tangles are only found in the TAU mice with rare tangles starting
to appear in cortex in some mice at 4 months. By 8 months, they
are seen in all mice in the hippocampus and cortex, and by
18 months, neurofibrillary tangles are present in almost all neu-
rons in these regions.634 Cell Reports 10, 633–644, February 3, 2015 ª2015 The AuthorsNo plaques or tangles were found in the cerebellum of any of
the mice, consistent with the lack of plaques in this region previ-
ously observed in mouse models (Manook et al., 2012) and the
very mild plaque load observed even at end stage in live imaging
or postmortem tissue from AD patients (Driscoll et al., 2012; Thal
et al., 2004).
Microarray Data
Little Change in the Endogenous Expression of Mouse
App, Psen1, or Mapt
We initially checked whether overexpression of human genes
had caused any compensatory effects on the equivalent mouse
genes. We found no evidence that mouse App, Psen1, or Mapt
were changed in expression in any of the APP or PSEN1 trans-
genic mice (Figure S3; Table S1). In TAU mice, expression levels
of mouse App andMapt were slightly reduced. This is an impor-
tant observation, as it means there is no evidence that expres-
sion of the human transgenes causes increases in expression
of any of these directly related mouse genes in a manner that
could result in a feed-forward loop for amyloid pathogenesis.
(As Psen1 was not detectable on the microarray, its expression
was tested with qPCR; Figure S3).
Genome-wide Expression Analysis
Differential gene expression is correlated with pathology in the
different lines of amyloid mice, with TAU mice showing later
changes but reaching similar numbers of differentially expressed
genes.
Initially, differential gene expression was examined across all
ages and all genotypes, particularly concentrating on large
changes in expression compared to WT mice (at least 2-fold;
false discovery rate [FDR] % 0.05). In all the amyloid lines (HO-
and HET-TASTPM, TAS10 [APP], and TPM [PSEN1]), the pattern
of gene expression was similar to the pattern of the pathology
described above (Table S2). As with pathology, the largest and
earliest effects in gene expression were in the double mutants,
particularly HO-TASTPMwith the HET-TASTPM showing a qual-
itatively similar pattern of change, albeit at a slightly lower level
throughout. Interestingly, when the two mutations were ex-
pressed separately in the TAS10 (APP) or TPM (PSEN1) mice,
very little change in gene expression was seen, again consistent
with the extent of pathology and confirming that the large pro-
gressive gene-expression changes are not primarily age related.
The exception in the single transgenics was a small number of
genes that were differentially expressed in the TPM mice at the
earliest age tested (2 months; Table S2). These included genes
related to brain development (Msx1, Otx2, and Zic4), consistent
with the known role of PSEN1 in development through its role in
Notch processing (Hartmann et al., 1999). This suggests that
these mice may have a slightly retarded hippocampal-develop-
ment profile.
As the expression changes seen in the different amyloid mice
showed a similar pattern except that they occurred at rates
related to the rate of plaque deposition and hence at different
ages, we will include all genotypes in the network analysis below
but otherwise restrict the description in this paper to the HO-
TASTPM mice, representing the most clearly measureable
changes. Other details are included in the supplemental tables
referred to throughout the text. In contrast in TAUmice, whereas
Figure 1. Development of Pathology in the Hippocampus of TAU, TASTPM, TAS10, and TPM Transgenic Mice
Representative images of the CA1 region in the hippocampus, immunostained with antibodies (green) for Ab-40 or phosphorylated tau (AT8) and nuclear stain
DAPI (blue). TAUmice show phosphorylated tau in neurons and dendrites, usually beginning at 8 months of age. At 18 months, the majority of neurons in the cell
layers contain phosphorylated tau in the cell body. HO-TASTPM mice show early and rapid development of amyloid plaques. HET-TASTPM show slower
development of mature plaques beginning at 8 months of age. (Rare small plaques seen at 4 months in most mice.) TAS10 (APP) mice develop sparse hip-
pocampal plaques by 18 months of age. TPM (PSEN1) mice show no evidence of amyloid deposition by 18 months. Inset: semiquantitative scores based on
pathology severity (0–5) of TAU, TASTPM, TAS10, and TPMmice. Error bars: SEM. The scale bar represents 50 mm. See Figure S1 for progression of pathology in
the cortex, which is similar to hippocampus in all groups.
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Figure 2. Frequency of Gene Expression Changes Compared to WT, FDR < 0.05, Occurring in HO-TASTPM and/or TAUMice at 18 Months of
Age in Hippocampus and Cortex
(A and B) Hippocampus.
(C and D) Cortex.
(A and C) x axes represent fold changes (increased expression, positive; decreased expression, negative; negative fold change defined as 1/(transgenic/WT
expression); gray area undefined [1 or 1, no change]; HO-TASTPM [red] and TAU [blue]; Y axes represent frequency of genes).
(B and D) Venn diagrams depicting the overlap between genes with increased or decreased expression in TAU and HO-TASTPM (>1.5-fold changes).
See Tables S2–S4 for numbers of genes for these and other genotypes and details of genes differentially expressed.the number of genes showing differential expression at
18 months was similar to HO-TASTPM, the changes occurred
considerably later, lagging several months behind the appear-
ance of neurofibrillary tangles, with relatively little change in
gene expression seen at earlier stages. Whereas hippocampal
and cortical patterns of expression were similar, although with
fewer genes affected in the cortex, very few genes were differen-
tially expressed in the cerebellum in any genotype, as expected.
The descriptions below thus relate to hippocampus unless
otherwise specified.
General Patterns of Changes 2–18 Months:
Heterogeneous Pattern of Early Gene Expression in
Hippocampus
In HO-TASTPM mice, a few genes involved in neuronal differen-
tiation or development showed differential increases in expres-
sion (e.g., Dlx1, Efna5, and Gap43) at 2 months of age before
true amyloid plaques developed (Table S4). By 4 months, genes
in these developmental categories showed a mixture of
increased and decreased expression when compared with WT
mice but stabilized to WT levels by 8 months.
A similar pattern was seen in synapse-related genes in HO-
TASTPM. At 4 months, 20 of these genes showed increased
expression compared to WT, whereas ten other genes within
this category showed lower expression together with signifi-
cantly decreased expression of 15 genes involved in calcium
signaling. These expression changes returned to WT levels
with age and the development of pathology, showing lower
expression in a few genes at 8months. However, in HO-TASTPM
at 18 months, synaptic gene expression was almost entirely at
WT levels (Tables S1 and S4).
In the TAU mice, the early pattern of expression changes for
synaptic genes was similar, showing a mixed picture of a few
genes increased and some decreased at 4 months as compared
to WT (Tables S2 and S4).
Again genes involved in the calcium signaling pathway showed
lower expression, whereas genes involved in cation channel ac-
tivity or regulation of neurogenesis were increased in expression.
These changes were again reversed at 8 months. However, by636 Cell Reports 10, 633–644, February 3, 2015 ª2015 The Authors18 months, when neurofibrillary tangles were present in almost
all neurons, a substantial decrease of expression of synaptic
genes was evident, consistent with a loss of synapses.
Hence, whereas early expression changes in synaptic genes
were similarly mixed at young ages in amyloid and TAU mice,
the loss of synaptic genes at later stages, likely related to loss
of synapses, was much more prominent in the TAU mice with lit-
tle change in amyloid mice.
In fact, in general, very few genes were decreased in expres-
sion in HO-TASTPM mice even at 18 months when the plaque
load was very heavy. When genes showing increased and
decreased expression (>2-fold; FDR < 0.05) were compared
separately at 18 months, we found that, in HO-TASTPM mice,
over 97% of the genes that showed differential expression
were increased compared to WT in both hippocampus and cor-
tex, with <3% showing decreased expression. In contrast, in the
TAU mice, 15% of differentially expressed genes in hippocam-
pus and 54% in cortex showed significantly lower expression
than in WT mice (Table S3).
Genes Common to HO-TASTPM and TAU Mice at 18
Months Are Involved in the Immune System
Wewent on to investigate whether there was an overlap between
these strongly differentially expressed genes in the oldest TAU
and the oldest HO-TASTPMmice and characterized the function
of such common genes using the Enrichment Analysis System-
atic Explorer (EASE) in DAVID (http://david.abcc.ncifcrf.gov;
Table S4).
At 18 months, a striking number of genes showed increased
expression (<2-fold) compared to WT mice in both the HO-
TASTPM and TAU mice, particularly in the hippocampus with
106 genes (52%) in common from a total of 202 overexpressed
genes and a similar proportion (48%) when the threshold was
lowered to 1.5-fold (Figures 2A and 2B; Table S3). The overlap-
ping genes were largely related to immune or inflammatory
responses, in both the hippocampus and cortex (Table S4). In
the HO-TASTPM mice, even those genes not common to the
TAU mice tended to fall into the immune response category. In
contrast, in TAU mice, nonoverlapping genes tended to be
Figure 3. Complete Disruption of the Gene Ontology Category ‘‘Antigen Processing and Protein Presentation’’ in HO-TASTPM
Each symbol corresponds to the expression of an individual gene (HO-TASTPM, red squares; WT, blue triangles). Progressive disruption of this functional
category starts at 4 months and with complete disruption by 18 months in both hippocampus and cortex. Hippocampus shows the largest expression changes,
followed by the cortex, with almost no change in the cerebellum. See Table S4 for completely disrupted Gene Ontology (GO) categories in HO-TASTPM and TAU
mice.involved in cell death or apoptosis (12 genes) and DNA pack-
aging or chromatin assembly and disassembly (12 genes; Table
S4), again suggesting that loss of neurones or synapses was
likely more prominent in these mice.
HO-TASTPM and TAU Mice Show Changes in Entire GO
Categories Involved in Immune Function
Gene Ontology (GO)-ANOVA analysis of complete functional
groupings of genes (by averaging member gene expression of
GOcategories with aminimumof 15 andmaximumof 300 genes)
also confirmed considerable disruption in the immune system.
Eighteen entire GO categories were differentially increased in
hippocampus of HO-TASTPM mice, and of these, eight were
also increased in cortex. Moreover, even at 8 months, eight
categories were increased in hippocampus and two in cortex.
These GO categories were again related to the immune res-
ponse. At 4months, two other GO categories related to hormone
activity and regulation were also increased in the hippocampus
of HO-TASTPM mice. The general pattern of disruption
confirmed the observations above of increasing disruption in
parallel with amyloid pathology in both hippocampus and to a
lesser extent cortex. but little if any disruption in cerebellum
(for example see Figure 3).
Nineteen GO categories were found to be altered in the TAU
mice at 18 months in the hippocampus and in the cortex; GO
categories increasing in TAU mice were all also increased inCthe HO-TASTPM (Table S4). No GO category was found dysre-
gulated at other ages or in the cerebellum at any age.
Analysis of Genes Defined as Risk Factors by
Alzheimer’s GWASs Show Dysregulation in Both
TASTPM and TAU Mice
Although our primary analysis was genome-wide, we were
particularly interested in investigating the effects on gene
expression for all the known risk genes for AD in order to dissect
how the development of pathology influences their expression
(Figure 4, see legend for list of genes tested; Table S1). Although
the fact that a variant of a particular gene represents a risk fac-
tor does not automatically imply that the normal sequence
cognate protein will be directly involved in the pathogenesis of
the disease, some of these genes would be likely to show
expression changes during disease progression. This will give
additional evidence of the identification of the risk genes, as
one of the weaknesses of GWASs comes from the fact that
the variants or loci identified can be some distance from the
protein-coding sequences of any gene, making the link to the
gene uncertain (Guerreiro and Hardy, 2011). Changes in these
genes would both contribute evidence to the validity of the
models but also add to the knowledge of their role in disease
progression. Interestingly, at 18 months in hippocampus, ex-
pression of the following GWAS loci risk genes was differentially
increased by at least 1.5-fold in both the HO-TASTPM and TAUell Reports 10, 633–644, February 3, 2015 ª2015 The Authors 637
Figure 4. Gene Expression Changes Rela-
tive to WT of Risk Factor or Other AD-
Related Genes
Largest symbols p < 0.0001 (** on Trem2 plot);
medium p < 0.01 (* on Trem2 plot). Small symbols,
no significant difference. For graphical represen-
tation here, errors are excluded, but individual
gene data are available at http://mouseac.org.
Arrows at the bottom indicate the time course from
appearance of plaques or neurofibrillary tangles.
Legend indicating colors of symbols and arrows
top right applies to all panels. Genes tested:
Abca7; Ace; Aif1; Ap2a2; Apoe; App; Bin1; Cd33;
Clu; Cugbp1; Dsg2; Echdc3; Frmd6; Gfap (astro-
cyte marker); Glra2 (neuron marker); Hs3st1;
Inpp5d; Mapt; Mef2c; Mog (oligodendrocyte
biomarker); Ms4a6d; Picalm; Psen2; Ptk2b; Rin3;
Slc24a4; Sorl1; Sqstm1; Trem2; Trip4; and
Zcwpw1 (genes underlined include >1.5-fold and
FDR p < 0.05 for at least one age). See Table S1 for
expression of other GWAS hits and Figure S3 for
PSen1 expression by qPCR.mice: Apoe; Cd33; Inpp5d; Ms4a6d; and Trem2. Of these,
Trem2 in HO-TASTPM mice showed the greatest differential
expression, reaching >5-fold WT levels by 18 months in both
hippocampus and cortex. Expression of all of these genes
was however already increased in hippocampus of HO-
TASTPM mice from 8 months and, in the case of Trem2, from
4 months onward in both cortex and hippocampus. In contrast,
in the TAU mice at 8 months, despite neurofibrillary tangles ap-
pearing in all mice, no changes in Trem2 expression were
evident, suggesting that the increase in Trem2 expression fol-638 Cell Reports 10, 633–644, February 3, 2015 ª2015 The Authorslows the appearance of tangles but with
some delay. Similar results were seen
for TAU mice in the other genes, with
very few genes following the time course
of the appearance of neurofibrillary
tangles but many showing differential
expression at 18 months. Among the im-
mune genes, increased expression of the
general microglial marker Iba1 (Aif1) sug-
gests proliferation of microglia numbers.
This began from early ages in TASTPM
mice but was not detectable until
18 months in TAU mice. This difference
was confirmed by qPCR in both the
same mice and independent mice (Fig-
ure 5A for Aif1 and Figure S2 for this
and other genes) as well as by immuno-
histochemistry for verification at the pro-
tein level (Figures 5B and 5C). However,
the even greater increases in Trem2 sug-
gest additionally a change in activation
state of the microglia with individual mi-
croglia increasing their Trem2 expres-
sion, as suggested in a previous study
comparing plaque-associated and pla-
que-free tissue in which TREM2 wasincreased but numbers of microglia were unchanged in an am-
yloid transgenic mouse line (Frank et al., 2008). This is also re-
flected in the stronger signal for CD68 (Figure 5D). Additionally,
two other known risk genes, Ptk2b and Slc24a4, were signifi-
cantly decreased by at least 33% in TAU mice at 18 months,
but not in HO-TASTPM, and Ap2a2 was slightly but significantly
decreased at 4 months in both TAU and HO-TASTPM (Figure 4).
Hence, it seems that at least some of the genes known to be risk
factors are indeed directly involved in the effects of increasing
Ab and/or altered tau function.
Figure 5. qPCR and Immunohistochemistry
Validate the Microarray Data and the Corre-
lation of Plaques Rather Than Tangles to
Immune Genes
(A) Iba expression from microarray data (points) is
reflected closely by qPCR analysis of mRNA in the
same mice (closed bars) and in independent mice
(open bars; black, WT; red, HO-TASTPM; blue,
Tau). Eight months of age. Error bars: SEM.
(B) Light micrographs of DAB-immunostained
brain sections for Iba1 to label microglia in the CA3
region of the hippocampus in Tau or HET-TASTPM
mice at 10 months of age. WT and transgenic
sample pairs stained simultaneously on the same
slide.
(C) Quantification of microglial counts; WT: n = 8
animals; TASTPM: n = 3; Tau: n = 5 (mean of three
sections per animal). As WT counts for the two
groups were not different, they were combined in
this graph. One-way ANOVA, post hoc analysis
TASTPM different from WT (p < 0.0001). Note that
microglia in HO-TASTPM mice were too dense to
count, and thus heterozygotes were used for this
experiment. Error bars: SEM.
(D) Triple-fluorescent immunofluorescent staining
confirming that the clustering of microglia was
around plaques in the TASTPM mice. Red, CD68;
green, Ab-42; blue, DAPI.
The scale bar in (B) represents 50 mm, and the
same scale bar represents 40 mm in (D). (See
further qPCR validation of this and other genes in
Figure S2 and qPCR of PSen1 in Figure S3.)Consistent with changes seen across neurodegenerative dis-
eases in humans, astrocyte marker Gfap was also increased
from 8 months onward in TAU and TASTPM mice (Figure 4).
Network Analysis of Differentially Expressed Genes in
the Transgenic Mice
Weighted Gene Co-expression Network Analysis (WGCNA)
was applied to genes with high variable expression with the
following aims: (1) to identify novel gene coexpression modules
and summarize the main enriched biological functions and
molecular pathways that are disrupted in the AD transgenic
models and (2) to investigate whether expression levels of
confirmed and proposed AD loci belong to specific modules
and to understand which genes they correlated with in putative
disease pathways. (See the Experimental Procedures for further
details).
Unsupervised WGCNAs were used to analyze the most-vari-
able genes (n = 3,904) determined by their coefficient of variance
and not in relation to clinical or pathological features.
Separate coexpression networks for the transgenic and WT
groups confirmed that nearly all of the networks of WT mice
were preserved in the transgenic mice. Overall, we found strong
evidence of preservation of the WTmodules (Z summary > 10) in
the transgenic modules in the three brain regions, indicating
similar basic transcriptional organization in the brain.
To investigate how groups of coexpressed genes showing
transcriptional differences between transgenic and WT mice
were related to the occurrence of amyloid plaques or neurofi-
brillary tangles, we constructed a coexpression network using
samples from all transgenic and WT mice throughout theCages tested. The expression levels of each module were sum-
marized by the first principal component and related to vari-
ables such as age (2, 4, 8, and 18 months), amyloid or tau
pathology, genotype (all transgenic versus WT mice), individual
transgenic lines, and interactions between these variables. In
addition, potential artifacts due to technical experiment vari-
ables, such as hybridization batch, were tested, though they
were not determined to be statistically significant, and therefore
excluded.
In the hippocampus, two significant modules of coexpressed
genes were identified: M1 (r2 = 0.43; p = 3 3 106), a module
enriched with genes associated with immune and inflammatory
processes and M2 (r2 = 0.5; p = 2 3 108), a module enriched
with genes involved in synapse and neurotransmitter trans-
port functions (Figure 6A; Table S5 for GO categories in M1
and M2).
The immune module, M1, was correlated with genetic modifi-
cation (r2 = 0.26; p = 0.005), age (r2 = 0.48; p = 73 108), mouse
line (r2 = 0.38; p = 4 3 105), and also with the interaction be-
tween age and genetic modification (r2 = 0.57; p = 3 3 1011)
and age and mouse line (r2 = 0.54; p = 7 3 1010) but was
most strongly positively correlated with amyloid pathology and
less strongly but still showing high statistical significance with
tau pathology (Figure 6Aii). Of all these relationships, the stron-
gest correlation was between the immune module M1 and amy-
loid pathology in the general analysis of genes from all mice. We
went on to investigate this correlation, removing the TAU mice
from this comparison, as they had a transgenic alteration not
related to plaque pathology. Including only amyloid and WTell Reports 10, 633–644, February 3, 2015 ª2015 The Authors 639
Figure 6. Analysis of Gene Coexpression
and the Relation of Significant Modules to
Amyloid or Tau Pathology
(A) Network analysis of the most-correlated genes
across all genotypes and ages. (i) Dendrogram of
average hierarchical gene clustering (modules are
divided at significant branch points in the
dendrogram). The y axis corresponds to the dis-
tance determined by the extent of topological
overlap. The first band below the x axis shows the
resulting automatically determined modules only
referring to correlation of gene expression without
biological considerations. The lower two bands
illustrates a measure of biological relevance
(‘‘gene significance’’ [GS]) of the modules in terms
of positive (red) or negative (blue) correlation of
participating genes to amyloid or tau pathology. (ii)
Module membership (measure of the correlation
between the gene-expression profile and the
module’s gene-expression profile) for genes from
all mice, as indicated in (i) plotted against GS. M1
(‘‘immune module’’) membership correlation with
amyloid (left) and tau (right) pathology. (iii) M2
(‘‘synapse module’’) membership correlation with
amyloid (left) or tau (right) pathology. The central
panels in both (ii) and (iii) list the functions of the
genes most strongly represented in the modules
illustrated, with the strongest correlation being M1
to amyloid pathology. BP and CC indicate whether
themodules are according to biological processes
or cellular compartments.
(B) As for (A) above, but only analyzing genes of
amyloid mice and WT. Note the very strong cor-
relation of M1 to plaque load when analysis is
restricted to amyloid mouse lines. (See Table S5
for details of GO categories for M1 and M2.)mice again brought out M1 as the strongest module and strongly
increased the correlation of M1 and amyloid pathology to a level
close to 1:1 (Figure 6B). Similar strong correlations were found in
the cortex. Again, whereas it is not unexpected that changes in
immune function may be a reaction to plaque deposition, the
strength of this correlation was unexpected. Hence, it seems
that amyloid pathology alone is sufficient to activate the immune
system and the role of tau pathology in this context is consi-
derably weaker. The earlier increases in immune function in
TASTPM mice compared to TAU mice were confirmed with
immunohistochemistry as outlined above (Figure 5). The micro-
glia were seen especially, but not entirely, to cluster around pla-
ques (Figure 5D).
In contrast, the synaptic module M2, whereas also correlating
with age (r2 = 0.27; p = 0.005) and the interaction between age
and genetic modification (r2 = 0.37; p = 6 3 105) and mouse
line (r2 =0.33; p = 33 104), correlated negatively with tau pa-640 Cell Reports 10, 633–644, February 3, 2015 ª2015 The Authorsthology but showed no significant corre-
lation with amyloid pathology (adjusted
p value > 0.01; Figure 6Aiii). The negative
correlation of synaptic genes to tau pa-
thology is consistent with postmortem
tissues from Alzheimer’s patients, where
synaptic loss has been shown to becorrelated with the presence of tau tangles in cortical pyramidal
neurons (Merino-Serrais et al., 2013).
Immune Module, AD Risk Loci, and Connectivity
Patterns
The immune module M1 was particularly of interest because it
included several of the human risk factors for AD, as defined
by GWASs. As expected, Trem2 and Cd33, as well as Inpp5d
andMs4a6d, were included. Having established the strong cor-
relation between gene significance (GS) and module member-
ship when all the amyloid mouse lines (HO- and HET-TASTPM,
TAS10, and TPM) and WT mice were considered together, we
went on to investigate which of the genes in this module were
of particular importance in terms of interconnectivity in the
network (Figure 7).
In a complex network, connectivity frequently follows a power
law distribution in which only a few nodes show very high
Figure 7. Network Analysis of Immune Genes
Network plot using VisANT reveals key drivers of the ‘‘immune’’ module (M1) using genes from eitherWT and amyloidmice (left) orWT and TAUmice (right). Genes
are connected to all other genes that show significant correlation of gene expression. Larger spheres represent ‘‘hub genes,’’ those showing the greatest number
of connections to other genes in the network.
(A) Hippocampus. The only difference in geneswith hub status between amyloid and TAUmice in hippocampus is Trem2, which is a hub gene in the amyloidmice,
but not in the TAU mice.
(B) Cortex. The amyloid mice show fewer hub genes than in hippocampus, but all except two of the hubs are in common with hippocampus whereas TAU mice
show a different group of hub genes. Circles and squares represent hub genes preserved between brain regions and/or genotypes. Red and blue arrows indicate
hub genes not having hub status in any other network plot. Open black arrow in right panels highlights nonhub Trem2.connectivity (Baraba´si and Oltvai, 2004). There is evidence to
suggest that genes with high connectivity (‘‘hub genes,’’ defined
here as genes with at least 15 connections) are crucial to the
integrity and proper functioning of the network, making them
excellent candidate genes for disease-association studies (Varki
et al., 2008). In order to compare the functional network in hippo-
campus and cortex, and to establish whether amyloid and TAU
mice were fundamentally different in the underlying pathways,
four networks of genes were constructed dependent on their
correlated expression, using genes from theM1 ‘‘immune’’ mod-
ule either fromWT + amyloid mice or WT + TAUmice in both hip-
pocampus and cortex.
Considering only the gene expression in the M1 immune
module in the hippocampus of the amyloid + WT mice, the
network identified was remarkably simple, centering around
only six hub genes (C1qa, C1qb, C1qg, Fcer1g, Hcph, and
Trem2; Figure 7A, left panel). Note that C1qa, C1qb, and
C1qg code for the three chains of C1q, one of the proteinsCthat make up the C1 complex, activation of which triggers the
classical pathway of the immune complement system (Ghai
et al., 2007), bringing the number of hub genes effectively
down to only four. In the cortex, a similar pattern was seen as
in the hippocampus for the amyloid mice but with only five
hub genes (C1qa, C1qb, Fcer1g, Trem2, and Tlr2), of which all
except Tlr2 are in common with the hippocampal network of
these mice. In the hippocampus, the TAU + WT mice also
showed almost identical hub genes with the exception of
Trem2, which, although still part of the correlated network,
lost its hub status. This is interesting in terms of the fact that var-
iations in TREM2 have recently been described as relatively
strong risk factors for developing Alzheimer’s disease (Guerreiro
et al., 2013; Jonsson et al., 2013) and here appear as particu-
larly important in the network of the amyloid rather than the
TAU mice. Considering these hub genes arise from over 600
genes in the immune module M1, the consistency in these three
networks is remarkable.ell Reports 10, 633–644, February 3, 2015 ª2015 The Authors 641
In contrast to the other three networks, in the cortex of the TAU
mice, the genes of the M1module form amore complex network
of correlations with ten hub genes, only two of which (C1qb and
Tlr2) are in common with nine hubs of any of the other networks.
Hence, C1qb is the only gene common to all four networks
whereas Tlr2 is specific to the two cortical networks. The remark-
able difference between the cortical network of the TAU mice
compared to other three very similar networks is interesting
and may suggest reasons why FTD-17 is primarily a cortical dis-
ease and shows very different characteristics to AD (Hutton
et al., 1998).
Conclusions
We have presented a database that not only goes further than
previous such studies in the number of models, ages, and brain
regions compared, but we also directly compare transgenic
mice with raised Ab and plaque pathology but no neurofibrillary
tangles to those with a tau mutation leading to tangle pathology
without plaques. Network analysis of this extensive database not
only validates the models in terms of the relevance of the mouse
gene expression to what is known of human genetics in Alz-
heimer’s disease but provides substantial insights into the
different effects of alterations in Ab and tau. In addition, we high-
light specific genes, particularly in the immune system, that may
influence the progression of the disease and reveal some of the
early synaptic changes that may be important in the onset of dis-
ease versus the late synaptic changes that are probably the
result of synaptic loss. The separation of the influence of amyloid
pathology on immune function and tau pathology on synaptic
loss suggests that targeting the development of tau pathology
will be the most effective in slowing cognitive decline late in
the disease, whereas targeting plaque pathology would de-
crease the activation of the immune system.
Not only are insights available from approaches such as those
outlined above, but every gene can be individually accessed us-
ing the interface provided. Access to this interface and to the
data providing information on gene expression for studies of
different aspects of dementia throughout pathology develop-
ment as well as normal aging of the hippocampus, cortex, and
cerebellum is available at http://www.mouseac.org.
EXPERIMENTAL PROCEDURES
Mice
All procedures were performed in agreement with the UK Animals (Scientific
Procedures) Act, 1986, with local ethical agreement and following the GlaxoS-
mithKline (GSK) statement on the use of animals. Mice of different genotypes
were killed by isoflurane overdose followed by cervical dislocation at 2, 4, 8, or
18 months, and one half of the hippocampus, cortex, and cerebellum were
dissected out and snap frozen for extraction of mRNA. The other half of the
brain was drop fixed in 4% paraformaldehyde for direct comparisons using
immunohistochemistry. Tissues from at least three male mice from each of
the following five transgenic lines, plus at least eight littermate controls from
the original parental lines, were collected. The five mouse lines analyzed
were as follows.
TAS10: human APP (K670N/M671L); heterozygous on Thy1 promoter (Ri-
chardson et al., 2003)
TPM: human PSEN1 (M146V); heterozygous on Thy1 promoter
HET-TASTPM: heterozygous crosses for both of the APP and PSEN1
transgenic lines642 Cell Reports 10, 633–644, February 3, 2015 ª2015 The AuthorsHO-TASTPM: as above but both transgenes bred to homozygosity
TAU: human microtubule-associated protein tau (MAPT) mutant P301L,
heterozygous on CaMKII promoter
WT: age-matched WT mice of the same C57Bl/6j backgroundHistology
Mouse brains were drop fixed in 4% paraformaldehyde and cryoprotected in
30% sucrose. For fluorescent immunostaining, brains were sectioned using a
Leica frozen microtome. Serial 30 mm thick sections (360 mm apart), cut
transverse to the hippocampus, were pretreated with 1% Chicago Sky blue
to reduce background and elastin fluorescence and processed for immunohis-
tochemistry. Sections were permeabilized in 0.3% Triton-X, blocked in 8%
horse serum, and incubated with appropriate primary antibodies overnight.
Amyloid plaques were examined using rabbit polyclonal Ab40, which recog-
nizes amino acids 34–40 in human Ab protein (1:300; Invitrogen), followed by
Alexa-488-conjugated secondary antibody (1:500; Abcam). Hyperphosphory-
lated tau was stained with mouse monoclonal biotinylated AT8, which recog-
nizes the Ser202/Thr205 phosphorylation site of human tau (1:300; Thermo
Scientific) and Alexa-488-conjugated streptavidin (1:500; Molecular Probes).
Microglia were stained with rat anti-CD68 antibody (Abd Serotec; 1:500),
followed by donkey anti-rat (1:1,000; Jackson Laboratories) secondary. Cell
nuclei were stained with DAPI (1:10,000; Sigma). Sections from WT mice
immunostained with primary and secondary antibodies were included in
each experiment, in addition to sections from 18 months transgenic brains
stained with appropriate secondary antibody only. Images were obtained us-
ing an EVOS Auto FL microscope (Fisher Scientific). Semiquantitative analysis
was performed by visually inspecting at least four serial sections of the brains
of each animal. Slides were randomized so that the assessor was blind to the
age of the mouse.
Glial immunostaining was performed on 10 mm thick cryosections (Leica
CM1950). Sections were pretreated with hydrogen peroxide and 0.1M sodium
citrate prior to incubation with rabbit anti-Iba1 (1:500; Wako) and processed
with peroxidase VECTASTAIN ABC kit and 3,30-diaminobenzidine (DAB) sub-
strate kit per manufacturer’s instructions (Vector Laboratories). Imaging was
performed on Zeiss Axiophot microscope (Carl Zeiss). For quantification, three
40,000 mm2 regions were selected in the CA3 region of the hippocampus and
microglia were quantified using ImageJ (NIH) software.
RNA Extraction and Microarrays
Total RNA from the hippocampus was isolated using the RNeasy Mini Kit
(QIAGEN). The quality and concentration of the total RNA was determined us-
ing a NanoDrop Spectrophotometer (A260:A280 and A260:A230 ratios). All
samples (transgenic andWT) were randomly hybridized to Illumina Ref8 v2 mi-
croarrays. cDNA labeling and hybridization were performed according to the
manufacturer’s instructions by AROS Applied Biotechnology.
Verification of Microarray Data with qPCR
As an addition to verification of previous microarray data (Lagraoui et al., 2012;
Trabzuni et al., 2011), we have verified the present microarray by qPCR on a
selection of genes shown to be differentially expressed in this data set. These
included neuronal genes that showed early differential expression at 2–
4 months and astrocytic and immune genes that were differentially expressed
at 8–18 months. qPCR was carried out both on the same tissue to check the
consistency with the microarray data as well as on samples in which the
mRNA was independently prepared from the brains of a different group of
mice. In both cases, the data were almost entirely consistent (Figure S2).
Prior to use, the primers were tested for specificity by performing a test PCR
reaction and resolving the samples on an agarose gel with ethidium bromide.
The cDNA samples were tested in triplicate in a 20 ml reaction volume in a 96-
well plate format, containing 250 nM of each oligonucleotide primer and SYBR
Green PCR Master Mix (BioRad). Negative control PCR reactions were also
performed in parallel on total RNA that had not been processed with reverse
transcriptase to test for the presence of genomic DNA in each sample with
each primer pair. The cycling parameters were: 3 min at 95C, followed by
40 cycles (95C for 10 s, annealing at 58C for 30 s, and extension at 72C
for 30 s), and then amelt-curve analysis was performed by holding the samples
at 95C for 1 min and then increasing the temperature from 60C to 95C in
0.5C increments every 5 s. The real-time PCRwas performed in a CFX96 sys-
temwith a C1000 thermal cycler (BioRad). We ensured that all qPCR reactions
produced a single peak with the melt curve analysis. The results were ex-
pressed as 2(gene of interest mean Ct value  control gene mean Ct value) for the qRT-
PCR experiments. In order to increase the accuracy of gene expression levels
for normalization, we used the mean of three internal control reference genes:
Rps28, Rps29, and Rpl4 (Vandesompele et al., 2002). Because the expression
ratio of ideal control reference genes should be the same across all samples,
we selected these reference genes among a set of 12 candidate reference
genes that also included b-actin and Rps18 in order to minimize the pairwise
variation in gene expression across hippocampal tissues from different
mice. The calculations were performed as described on the geNorm website
(http://medgen.ugent.be/jvdesomp/genorm/).
Data Analysis
All analyses were performed using R software and Partek Genomics Suite
(Partek).
Raw expression data were log2 transformed, and all samples were quantile
normalized together. Individual probes were excluded from analyses if the
detection p value was >0.05 in more than 50% of the samples in a given group
at any age. Also, samples were excluded if <95% of the probes were detected.
After these quality control steps, data were available for 113 hippocampus
samples, 113 cortex samples, and 111 cerebellum samples representing
12,588 genes. Region, age, mouse strain and line, the interactions between
these variables, as well as hybridization batch accounted for most of the
data variance and were therefore included in the regression model. Unless
otherwise specified, a conservative statistical threshold of FDR < 0.05 and
minimum fold difference R 1.5 between sample groups was used in all
comparisons.
EASE (Subramanian et al., 2005) was used to identify enriched biological
themes in gene lists using the DAVID database (http://david.abcc.ncifcrf.
gov). EASE uses amodified Fisher’s exact test to determine whether the genes
assigned to a GO, Kyoto Encyclopedia of Genes and Genomes grouping, and
other experimentally derived genes that are overrepresented in gene cate-
gories relative to the population of genes investigated.
GO-ANOVA (Partek) was also used to find (1) differentially expressed func-
tional groups of genes between the transgenic and control mice in the three
brain regions and (2) changes in the pattern of gene expression within the func-
tional group. In the first type of analysis, an ANOVA is performed at the gene
level, but the result refers to the level of the functional group by averaging
member gene results. In the second type of analysis, Z tests are used to
compare the difference between each gene and the rest of the genes in the
functional group, obtaining a disruption score that is the minimum p value
from the Z test. Hippocampus, cortex, and cerebellum samples were analyzed
separately after removing batch effect, and analyseswere performed with their
residuals.
For WGCNAs, unsigned coexpression networks were built using the
WGCNA package in R. Genes with variable expression patterns (coefficient
of variation >5%) and normalized Log2 expression values of at least 5 in any
of the five transgenic groups, four ages, and three regions were selected for
network analyses (Oldham et al., 2006). Therefore, 3,904 of the most-variable
genes in a given tissue, age, disease state, and AD transgenic model were
included in the analyses. WGCNA were performed on the selected genes as
previously described (Horvath et al., 2006; Oldham et al., 2006; Zhang and
Horvath, 2005). For each set of genes, a pairwise correlation matrix was
computed and an adjacency matrix was calculated by raising the correlation
matrix to a power. The power of 12 was chosen using the scale-free topology
criterion and was used for each network using all AD transgenic and WT sam-
ples in each brain region.
For each pair of genes, a robust measure of network interconnectedness
(topological overlap measure; Yip and Horvath, 2007) was calculated based
on the adjacency matrix. The topological overlap-based dissimilarity was
then used as input for average linkage hierarchical clustering: groups of genes
based on the topological overlap of their connectivity. Branches of the result-
ing clustering tree were defined as gene modules (Langfelder et al., 2008). To
cut the branches, we used hybrid dynamic tree cutting, a minimum moduleCsize of 30 genes, and a minimum height for merging modules at 0.25. Each
module was summarized by the first principal component of the scaled (stan-
dardized) module expression profiles. For each module, the module member-
ship measure (aka module-eigengene-based connectivity kME) was defined
as the correlation between gene-expression values and the module eigen-
gene. Genes were assigned to amodule if they had a highmodulemembership
(kME > 0.7). Each module was assigned a unique color identifier, and genes
that did not fulfil these criteria for any of the modules were assigned to the
gray module. For the cell-type-marker-enrichment analysis, we utilized the
userListEnrichment function (Miller et al., 2011) in the WGCNA library. This
function measures list enrichment between input lists of genes and files con-
taining user-defined lists of genes using a hypergeometric test. We utilized
the predefined brain lists corresponding to cell-type markers (astrocytes, neu-
rons, oligodendrocytes, microglia, and macrophages) and genes found to be
up- or downregulated with AD in any mouse or brain region.
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